Developer docs
API playgroundTry for free, no card

Search company profiles

Polyplus-transfection

Full company profile

uuid000bov4

Namestring
Polyplus-transfection
Legal namestring
Polyplus-Transfection SA
Company typeenum
Private
Founded yearint
2001
Descriptiontext

Polyplus, founded in 2001 and headquartered in Illkirch-Graffenstaden, France, develops and commercializes nucleic acid delivery technologies and related services for the biopharmaceutical and life sciences research markets. Its core technology portfolio spans lipid-based nanoparticles (LNPs), PEI-based transfection reagents, and cationic polymer formulations used to deliver DNA, RNA, siRNA, and oligonucleotides into cells, both in vitro and in vivo. Flagship products include FectoVIR®-AAV and FectoVIR®-LV (transfection reagents for recombinant AAV and lentiviral vector manufacturing), PEIpro® (PEI-based viral vector production reagent), the in vivo-jetRNA®+ and in vivo-jetPEI® reagents, and the LipidBrick® proprietary cationic lipid library for LNP formulation. The company also offers nucleic acid and protein services—plasmid engineering, plasmid manufacturing (research, HQ, and GMP grades), protein manufacturing, whole-plasmid next-generation sequencing, and a free Design of Experiments (DoE) consulting service—acquired or built around the December 2022 acquisition of Xpress Biologics and the Bio Elpida manufacturing site.

The company serves four primary use-case segments: cell and gene therapy (viral vector production for CAR-T, TCR, and gene editing), RNA/DNA therapeutics (LNP formulation for mRNA vaccines and therapeutics, including CRISPR delivery), protein production (CHO and HEK-293 transient expression for antibodies and proteins), and life sciences research (transfection reagents and the Easy Plasmid Service starting at $249). Customer logos span major bioprocessing names including Corning Life Sciences, Lonza, Genethon, MolMed, Vigene Biosciences, and Vivebiotech, alongside unnamed biopharmaceutical manufacturers.

Polyplus operates a hybrid revenue model combining one-time sales of transfection reagents and kits (quote-based pricing for GMP and large-scale items; fixed unit pricing for catalog and research products) with professional and managed services revenue from plasmid and protein manufacturing and sequencing. Distribution combines a direct enterprise salesforce with a global network of more than 100 distributor partners, supported by offices in France (Illkirch, Loos, Saint Priest), Belgium (Milmort, via Xpress Biologics), the United States (New York), and China (Shanghai). Since July 2023, Polyplus has operated as a wholly-owned subsidiary of Sartorius AG following the German bioprocessing group's €2.4 billion (~$2.6 billion) acquisition completed in March 2023.

Short descriptiontext

Polyplus (part of Sartorius since July 2023) develops and commercializes nucleic acid delivery technologies—including lipid nanoparticles, PEI-based reagents, and cationic polymers—alongside plasmid and protein manufacturing services, serving biopharmaceutical and life-sciences customers in cell and gene therapy, RNA/DNA therapeutics, protein production, and research.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersIllkirch-graffenstaden, France
HQ citystring
Illkirch-graffenstaden
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
transfection reagents, nucleic acid delivery, viral vector manufacturing, plasmid engineering services, lipid nanoparticle formulation
Industry3 codes
PRIMARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAC
Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAKAE
Plasmid DNA & mRNA Manufacturing Services
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Plastics Material and Resin Manufacturing325211
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Plastic Materials, Synth Resins & Nonvulcan Elastomers2821
Product category
Transfection Reagents for Bioprocessing
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model5 records
1Transfection Reagents and Kits
TypeOne Time License
Description

Sale of transfection reagents including PEI-based products, lipid nanoparticles, and cationic polymers for nucleic acid delivery in research, process development, and GMP grades.

polyplus-sartorius.com
2Plasmid Engineering Services
TypeProfessional Services
Description

Custom plasmid design and manufacturing services for research, HQ, and GMP grades, providing integrated solutions from DNA plasmid design to analytical testing.

polyplus-sartorius.com
3Plasmid Manufacturing Services
TypeManaged Services
Description

Contract manufacturing of plasmid DNA using unique processes for Research, HQ (High Quality), and GMP grades with full analytical testing.

polyplus-sartorius.com
4Protein Manufacturing Services
TypeManaged Services
Description

Process development to manufacturing of proteins at Research, HQ and GMP grades, covering the full product lifecycle.

polyplus-sartorius.com
5Sequencing and Analysis Services
TypeProfessional Services
Description

Whole plasmid sequencing services using Next Generation Sequencing technology providing 100% coverage.

polyplus-sartorius.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Pricing details1 tier
1Easy Plasmid Service - Ready-to-use research plasmids
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Easy Plasmid Service starting at $249, includes fully sequenced plasmids ready for research with miniprep included.

polyplus-sartorius.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 15 records shown
1FectoVIR®
Description

Transfection reagent for viral vector manufacturing (AAV and lentiviral vectors)

polyplus-sartorius.com
+14 more records
Core offering1 text field

Polyplus develops, manufactures, and sells transfection and nucleic acid delivery reagents — including PEI-based polymers, lipid nanoparticles, and cationic formulations — for delivery of DNA, RNA, siRNA, and oligonucleotides in research, bioproduction, and therapeutic applications. The portfolio is complemented by custom plasmid engineering, plasmid and protein contract manufacturing services, and whole-plasmid sequencing at research, HQ, and GMP grades.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 48-hour turnaround for scientific support inquiries
+4 more records
Product overview1 text field

Polyplus, part of Sartorius, is a platform-plus-services company offering a broad portfolio of transfection/delivery reagents, nucleic acid services, and protein manufacturing. The core product portfolio centers on transfection reagents organized by application: viral vector production reagents (FectoVIR-AAV, FectoVIR-LV, PEIpro) for cell and gene therapy manufacturing; in vivo delivery reagents (in vivo-jetRNA+, in vivo-jetPEI, LipidBrick Library) for RNA/DNA therapeutics; and in vitro transfection reagents (jetOPTIMUS, jetPRIME, jetMESSENGER, jetPEI, PULSin, INTERFERin, FectoPRO, FectoCHO) for life sciences and protein production research. The services tier — added through the 2022 acquisition of Xpress Biologics — includes plasmid engineering, plasmid manufacturing (research to GMP), whole plasmid sequencing, and the Easy Plasmid Service. A protein manufacturing service and a Viral Vector DOE service bridge the reagent and service offerings. The portfolio is unified by its focus on nucleic acid delivery across the workflow: from research-grade in vitro transfection through viral vector production scale-up to GMP-grade in vivo delivery reagents.

Product and service10 records
1FectoVIR®-AAV
CategoryTransfection Reagent
Description

Transfection reagent designed for large-scale recombinant AAV (rAAV) manufacturing. Available at research and GMP grade for production at any scale from benchtop to 2000L bioreactor, targeting improved process economics for gene therapy vector production.

2FectoVIR®-LV
CategoryTransfection Reagent
Description

Lentiviral vector (LV) transfection reagent designed to improve lentiviral titers in HEK-293 suspension cell systems. Offers cost-effective LV production for both small and large scale suspension systems, reducing DNA requirements while boosting productivity.

3PEIpro®
CategoryTransfection Reagent
Description

PEI-based DNA transfection reagent positioned as the #1 leader for small to large scale viral vector manufacturing. Offers flexibility and scalability for process development through commercial production of viral vectors.

4in vivo-jetRNA®+
CategoryTransfection Reagent
Description

Ready-to-use lipid-based nanoparticle transfection reagent specifically developed for in vivo mRNA delivery. Enables targeted delivery of mRNA therapeutics and vaccines using pre-formed LNPs.

5LipidBrick® Library
CategoryTransfection Reagent
Description

Novel range of proprietary cationic lipids dedicated to the formulation of LNPs (lipid nanoparticles) for development of mRNA-based vaccines and therapeutics. Supports expansion of LNP delivery beyond liver targeting.

6in vivo-jetPEI®
CategoryTransfection Reagent
Description

Ready-to-use cationic polymer reagent recommended for in vivo transfection of DNA, siRNA, miRNA, shRNA, and other oligonucleotides. Established as a gold standard for in vivo nucleic acid delivery in research applications.

7FectoPRO®
CategoryTransfection Reagent
Description

Transfection reagent specifically optimized for transient protein and antibody expression in CHO and HEK293 cells. Supports high-yield protein production for biopharmaceutical research and development.

8FectoCHO® Expression System
CategoryTransfection Reagent
Description

Expression system optimized for culture and transient protein expression in all CHO cell types. Designed to enhance functional protein and antibody production in mammalian expression systems.

9jetOPTIMUS®
CategoryTransfection Reagent
Description

Innovative cationic nanotechnology developed to improve DNA transfection efficiency in hard-to-transfect cells. Marketed as a best-in-class DNA transfection reagent for challenging cell types.

10jetPRIME®
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-12-08
Description

Polyplus completed the acquisition of Xpress Biologics in December 2022 to expand its plasmid DNA capabilities. The acquisition strengthens Polyplus's ability to provide integrated solutions from plasmid design through transfection reagents to manufacturing.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Mirus Bio develops TransIT®-brand transfection reagents for nucleic acid delivery in research and bioprocessing, directly competing with Polyplus's jet-series and FectoVIR product lines.

TypeBroad incumbent
Description

Thermo Fisher's Lipofectamine and broader bioproduction portfolio compete with Polyplus transfection reagents and plasmid/CDMO services across both research and GMP manufacturing.

3Merck KGaA (Life Science)
TypeBroad incumbent
Description

Merck offers FuGENE® transfection reagents and BioReliance® bioproduction services, overlapping with Polyplus's reagent and GMP manufacturing offerings within a far broader portfolio.

TypeEmerging player
Description

MaxCyte provides electroporation-based flow transfection technology and licensing for cell therapy developers, an adjacent non-viral nucleic acid delivery approach overlapping with Polyplus's reagent-based delivery solutions.

TypeDirect peer
Description

Aldevron supplies GMP-grade plasmid DNA, mRNA, and proteins to cell and gene therapy developers, directly competing with Polyplus's plasmid manufacturing and protein manufacturing services.

TypeBroad incumbent
Description

Lonza is a leading CDMO offering plasmid, viral vector, and bioprocess services to the same biopharma customers Polyplus serves, and is also a featured partner in Polyplus's customer base.

TypeBroad incumbent
Description

Catalent provides plasmid, viral vector, and cell therapy manufacturing services with a broad biopharma customer base, competing with Polyplus's upstream plasmid and process services offerings.

TypeEmerging player
Description

GenScript offers plasmid services, gene synthesis, and cell therapy products, providing overlapping nucleic acid and protein services relevant to Polyplus's reagent and plasmid manufacturing portfolio.

9Cobra Biologics (Charles River)
TypeDirect peer
Description

Cobra Biologics provides GMP plasmid and viral vector manufacturing services for gene therapy and DNA vaccine developers, directly competing with Polyplus's plasmid manufacturing services.

TypeBroad incumbent
Description

Cytiva supplies bioprocessing equipment, resins, and consumables used alongside Polyplus reagents in upstream biologics and viral vector manufacturing workflows within Sartorius's broader competitive landscape.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Polyplus-transfection

Transfection Reagents for Bioprocessingpolyplus-transfection.com

Polyplus (part of Sartorius since July 2023) develops and commercializes nucleic acid delivery technologies—including lipid nanoparticles, PEI-based reagents, and cationic polymers—alongside plasmid and protein manufacturing services, serving biopharmaceutical and life-sciences customers in cell and gene therapy, RNA/DNA therapeutics, protein production, and research.

What Polyplus-transfection does

Polyplus, founded in 2001 and headquartered in Illkirch-Graffenstaden, France, develops and commercializes nucleic acid delivery technologies and related services for the biopharmaceutical and life sciences research markets. Its core technology portfolio spans lipid-based nanoparticles (LNPs), PEI-based transfection reagents, and cationic polymer formulations used to deliver DNA, RNA, siRNA, and oligonucleotides into cells, both in vitro and in vivo. Flagship products include FectoVIR®-AAV and FectoVIR®-LV (transfection reagents for recombinant AAV and lentiviral vector manufacturing), PEIpro® (PEI-based viral vector production reagent), the in vivo-jetRNA®+ and in vivo-jetPEI® reagents, and the LipidBrick® proprietary cationic lipid library for LNP formulation. The company also offers nucleic acid and protein services—plasmid engineering, plasmid manufacturing (research, HQ, and GMP grades), protein manufacturing, whole-plasmid next-generation sequencing, and a free Design of Experiments (DoE) consulting service—acquired or built around the December 2022 acquisition of Xpress Biologics and the Bio Elpida manufacturing site.

The company serves four primary use-case segments: cell and gene therapy (viral vector production for CAR-T, TCR, and gene editing), RNA/DNA therapeutics (LNP formulation for mRNA vaccines and therapeutics, including CRISPR delivery), protein production (CHO and HEK-293 transient expression for antibodies and proteins), and life sciences research (transfection reagents and the Easy Plasmid Service starting at $249). Customer logos span major bioprocessing names including Corning Life Sciences, Lonza, Genethon, MolMed, Vigene Biosciences, and Vivebiotech, alongside unnamed biopharmaceutical manufacturers.

Polyplus operates a hybrid revenue model combining one-time sales of transfection reagents and kits (quote-based pricing for GMP and large-scale items; fixed unit pricing for catalog and research products) with professional and managed services revenue from plasmid and protein manufacturing and sequencing. Distribution combines a direct enterprise salesforce with a global network of more than 100 distributor partners, supported by offices in France (Illkirch, Loos, Saint Priest), Belgium (Milmort, via Xpress Biologics), the United States (New York), and China (Shanghai). Since July 2023, Polyplus has operated as a wholly-owned subsidiary of Sartorius AG following the German bioprocessing group's €2.4 billion (~$2.6 billion) acquisition completed in March 2023.

Polyplus-transfection firmographics

Firmographics
Name
Polyplus-transfection
Legal name
Polyplus-Transfection SA
Website
https://polyplus-transfection.com
Company type
Private
Founded year
2001
Operating status
Operating
Headcount range
1–10 employees
Short description
Polyplus (part of Sartorius since July 2023) develops and commercializes nucleic acid delivery technologies—including lipid nanoparticles, PEI-based reagents, and cationic polymers—alongside plasmid and protein manufacturing services, serving biopharmaceutical and life-sciences customers in cell and gene therapy, RNA/DNA therapeutics, protein production, and research.
Ownership category
akta.pro rank

Polyplus-transfection industry classification

Industry
Product category
Transfection Reagents for Bioprocessing
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Plastics Material and Resin Manufacturing (325211)
SIC
Biological Products, (No Disgnostic Substances) (2836), Plastic Materials, Synth Resins & Nonvulcan Elastomers (2821)
akta.pro industry
PRIMARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAC
Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAKAE
Plasmid DNA & mRNA Manufacturing Services

Keywords

  • Transfection reagents
  • Nucleic acid delivery
  • Viral vector manufacturing
  • Plasmid engineering services
  • Lipid nanoparticle formulation

Where Polyplus-transfection is headquartered

Location

Headquarters

HQ city
Illkirch-graffenstaden
HQ country
France
HQ region
Europe

Offices6 records

Markets served

Polyplus-transfection business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Transfection Reagents and Kits: Sale of transfection reagents including PEI-based products, lipid nanoparticles, and cationic polymers for nucleic acid delivery in research, process development, and GMP grades.
  2. Plasmid Engineering Services: Custom plasmid design and manufacturing services for research, HQ, and GMP grades, providing integrated solutions from DNA plasmid design to analytical testing.
  3. Plasmid Manufacturing Services: Contract manufacturing of plasmid DNA using unique processes for Research, HQ (High Quality), and GMP grades with full analytical testing.
  4. Protein Manufacturing Services: Process development to manufacturing of proteins at Research, HQ and GMP grades, covering the full product lifecycle.
  5. Sequencing and Analysis Services: Whole plasmid sequencing services using Next Generation Sequencing technology providing 100% coverage.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goEasy Plasmid Service - Ready-to-use research plasmids

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Polyplus-transfection product offering

Product offering

Core offering

Polyplus develops, manufactures, and sells transfection and nucleic acid delivery reagents — including PEI-based polymers, lipid nanoparticles, and cationic formulations — for delivery of DNA, RNA, siRNA, and oligonucleotides in research, bioproduction, and therapeutic applications. The portfolio is complemented by custom plasmid engineering, plasmid and protein contract manufacturing services, and whole-plasmid sequencing at research, HQ, and GMP grades.

Product overview

Polyplus, part of Sartorius, is a platform-plus-services company offering a broad portfolio of transfection/delivery reagents, nucleic acid services, and protein manufacturing. The core product portfolio centers on transfection reagents organized by application: viral vector production reagents (FectoVIR-AAV, FectoVIR-LV, PEIpro) for cell and gene therapy manufacturing; in vivo delivery reagents (in vivo-jetRNA+, in vivo-jetPEI, LipidBrick Library) for RNA/DNA therapeutics; and in vitro transfection reagents (jetOPTIMUS, jetPRIME, jetMESSENGER, jetPEI, PULSin, INTERFERin, FectoPRO, FectoCHO) for life sciences and protein production research. The services tier — added through the 2022 acquisition of Xpress Biologics — includes plasmid engineering, plasmid manufacturing (research to GMP), whole plasmid sequencing, and the Easy Plasmid Service. A protein manufacturing service and a Viral Vector DOE service bridge the reagent and service offerings. The portfolio is unified by its focus on nucleic acid delivery across the workflow: from research-grade in vitro transfection through viral vector production scale-up to GMP-grade in vivo delivery reagents.

Differentiator

Problem solved

Functional benefit

Brands

  • FectoVIR®: Transfection reagent for viral vector manufacturing (AAV and lentiviral vectors)
  • PEIpro®
  • in vivo-jetRNA®+
  • LipidBrick®
  • in vivo-jetPEI®
  • FectoPRO®
  • FectoCHO® Expression System
  • jetOPTIMUS®
  • jetPRIME®
  • jetMESSENGER®
  • jetPEI®
  • PULSin®
  • INTERFERin®
  • pPLUS®
  • Polyplus Database

Products and services

  • FectoVIR®-AAV Transfection reagent designed for large-scale recombinant AAV (rAAV) manufacturing. Available at research and GMP grade for production at any scale from benchtop to 2000L bioreactor, targeting improved process economics for gene therapy vector production.
  • FectoVIR®-LV Lentiviral vector (LV) transfection reagent designed to improve lentiviral titers in HEK-293 suspension cell systems. Offers cost-effective LV production for both small and large scale suspension systems, reducing DNA requirements while boosting productivity.
  • PEIpro® PEI-based DNA transfection reagent positioned as the #1 leader for small to large scale viral vector manufacturing. Offers flexibility and scalability for process development through commercial production of viral vectors.
  • in vivo-jetRNA®+ Ready-to-use lipid-based nanoparticle transfection reagent specifically developed for in vivo mRNA delivery. Enables targeted delivery of mRNA therapeutics and vaccines using pre-formed LNPs.
  • LipidBrick® Library Novel range of proprietary cationic lipids dedicated to the formulation of LNPs (lipid nanoparticles) for development of mRNA-based vaccines and therapeutics. Supports expansion of LNP delivery beyond liver targeting.
  • in vivo-jetPEI® Ready-to-use cationic polymer reagent recommended for in vivo transfection of DNA, siRNA, miRNA, shRNA, and other oligonucleotides. Established as a gold standard for in vivo nucleic acid delivery in research applications.
  • FectoPRO® Transfection reagent specifically optimized for transient protein and antibody expression in CHO and HEK293 cells. Supports high-yield protein production for biopharmaceutical research and development.
  • FectoCHO® Expression System Expression system optimized for culture and transient protein expression in all CHO cell types. Designed to enhance functional protein and antibody production in mammalian expression systems.
  • jetOPTIMUS® Innovative cationic nanotechnology developed to improve DNA transfection efficiency in hard-to-transfect cells. Marketed as a best-in-class DNA transfection reagent for challenging cell types.
  • jetPRIME®

Quantifiable outcome

  • 48-hour turnaround for scientific support inquiries
  • +4 more outcomes

Companies that use Polyplus-transfection

Customer profile

Named customers7 records

Segments4 records

Ideal customer profiles4 records

Polyplus-transfection technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Polyplus-transfection partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Xpress BiologicscoreStrategic or Co-development Partner · 8 December 2022Polyplus completed the acquisition of Xpress Biologics in December 2022 to expand its plasmid DNA capabilities. The acquisition strengthens Polyplus's ability to provide integrated solutions from plasmid design through transfection reagents to manufacturing.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Polyplus-transfection competitors and assessment

Company assessment

Direct peers

  • Mirus Bio: Mirus Bio develops TransIT®-brand transfection reagents for nucleic acid delivery in research and bioprocessing, directly competing with Polyplus's jet-series and FectoVIR product lines.
  • Aldevron (Danaher): Aldevron supplies GMP-grade plasmid DNA, mRNA, and proteins to cell and gene therapy developers, directly competing with Polyplus's plasmid manufacturing and protein manufacturing services.
  • Cobra Biologics (Charles River): Cobra Biologics provides GMP plasmid and viral vector manufacturing services for gene therapy and DNA vaccine developers, directly competing with Polyplus's plasmid manufacturing services.

Broad incumbents

  • Thermo Fisher Scientific: Thermo Fisher's Lipofectamine and broader bioproduction portfolio compete with Polyplus transfection reagents and plasmid/CDMO services across both research and GMP manufacturing.
  • Merck KGaA (Life Science): Merck offers FuGENE® transfection reagents and BioReliance® bioproduction services, overlapping with Polyplus's reagent and GMP manufacturing offerings within a far broader portfolio.
  • Lonza: Lonza is a leading CDMO offering plasmid, viral vector, and bioprocess services to the same biopharma customers Polyplus serves, and is also a featured partner in Polyplus's customer base.
  • Catalent: Catalent provides plasmid, viral vector, and cell therapy manufacturing services with a broad biopharma customer base, competing with Polyplus's upstream plasmid and process services offerings.
  • Cytiva: Cytiva supplies bioprocessing equipment, resins, and consumables used alongside Polyplus reagents in upstream biologics and viral vector manufacturing workflows within Sartorius's broader competitive landscape.

Emerging players

  • MaxCyte: MaxCyte provides electroporation-based flow transfection technology and licensing for cell therapy developers, an adjacent non-viral nucleic acid delivery approach overlapping with Polyplus's reagent-based delivery solutions.
  • GenScript: GenScript offers plasmid services, gene synthesis, and cell therapy products, providing overlapping nucleic acid and protein services relevant to Polyplus's reagent and plasmid manufacturing portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Polyplus-transfection social profiles

Digital presence

Polyplus-transfection compliance and trust

Trust signal

Compliance1 record

Polyplus-transfection financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Polyplus-transfection leadership team

Management profile

Number of profiles

Profiles1 record

Polyplus-transfection subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Polyplus-transfection funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Polyplus-transfection M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Polyplus-transfection

What does Polyplus-transfection do?

Polyplus develops, manufactures, and sells transfection and nucleic acid delivery reagents — including PEI-based polymers, lipid nanoparticles, and cationic formulations — for delivery of DNA, RNA, siRNA, and oligonucleotides in research, bioproduction, and therapeutic applications. The portfolio is complemented by custom plasmid engineering, plasmid and protein contract manufacturing services, and whole-plasmid sequencing at research, HQ, and GMP grades.

Is Polyplus-transfection a public or private company?

Polyplus-transfection is a private company. It is classified as corporate owned and is currently operating.

When was Polyplus-transfection founded?

Polyplus-transfection was founded in 2001. It employs 1 to 10 people.

Where is Polyplus-transfection based?

Polyplus-transfection is headquartered in Illkirch-graffenstaden, France, in the Europe region.

How does Polyplus-transfection make money?

Five revenue lines are on record. Transfection Reagents and Kits are the primary driver. The others are plasmid Engineering Services, plasmid Manufacturing Services, protein Manufacturing Services and sequencing and Analysis Services.

Who are Polyplus-transfection's main competitors?

Direct peers on record are Mirus Bio, Aldevron (Danaher) and Cobra Biologics (Charles River). Broad incumbents are Thermo Fisher Scientific, Merck KGaA (Life Science), Lonza, Catalent and Cytiva. Emerging players are MaxCyte and GenScript.

Does Polyplus-transfection have an API?

No public API is recorded for Polyplus-transfection.

What industry is Polyplus-transfection in?

Polyplus-transfection's product category is Transfection Reagents for Bioprocessing. Its primary akta.pro industry code is HLAAACAN, Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream), with a secondary code of HLAAACAC, Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comSegment Evaluation and Principal Growth Areas in the Bioprocess Bags MarketThe bioprocess bags market is projected to grow from its current size to $8.14 billion by 2030, with a compound annual growth rate of 16.3%, driven by increasing demand for biologics, vaccines, and cell and gene therapies. In March 2023, German pharmaceutical equipment provider Sartorius AG acquired France-based Polyplus for $2.6 billion to strengthen its cell and gene therapy capabilities. In January 2025, Thailand-based vaccine manufacturer BioNet won a BARDA Patch Forward Prize in collaboration with Germany's LTS Lohmann Therapie-Systeme AG for developing a dissolvable microneedle patch platform for mRNA vaccine delivery.openPR.comOutlook on the Transfection Reagents and Equipment Market: Major Segments, Strategic Developments, and Leading CompaniesThe transfection reagents and equipment market is projected to grow to $2.97 billion by 2030, representing an 11.3% compound annual growth rate, driven by CRISPR technology adoption, gene therapy research, and precision medicine investments. A notable transaction in the sector is Sartorius AG's acquisition of Polyplus-Transfection SA for $2.6 billion in March 2023, strengthening Sartorius's position in cell and gene therapy. Additionally, China's Yeasen Biotechnology received FDA Drug Master File acceptance in July 2025 for its GMP-grade UltraAAV PEI Transfection Reagent, highlighting competitive innovation in viral vector production tools.BioProcess InternationalAAV Platforms Challenges and OpportunitiesABL Europe and Polyplus (a Sartorius company) collaborated to optimize adeno-associated virus (AAV) vector manufacturing processes using design-of-experiments (DoE) strategies, with validation studies conducted from small-scale shake flasks through 2-L bioreactors. Polyplus's FectoVIR-AAV transfection reagent demonstrated at least twofold higher titers compared to the PEIpro reagent across multiple AAV serotypes, with the highest performance achieved at 0.5 µg DNA per 10^6 cells and higher cell-seeding densities. The article emphasizes that as gene therapy clinical trials grow (1,250 AAV trials in Europe, 669 in the US, 223 in Asia-Pacific), the industry must improve manufacturing efficiency through intensified processes to meet rising demand for viral vectors while reducing costs per dose.MarketScreenerSartorius Issues $3.22 Billion in Bonds for Polyplus Bridge FinancingSartorius issued 3 billion euros ($3.22 billion) in bonds to repay bridge financing for its acquisition of Polyplus and for general corporate purposes. The bonds were issued through subsidiary Sartorius Finance in four tranches with maturities between three and 12 years, and the company has applied to list them on the Luxembourg Stock Exchange.SartoriusSartorius completes acquisition of PolyplusSartorius has successfully completed the acquisition of the French company Polyplus on July 18, 2023, after securing the necessary regulatory approvals. Polyplus specializes in innovative technologies for cell and gene therapies, with its transfection reagents being crucial for manufacturing viral vectors. This acquisition will broaden Sartorius's portfolio to include various technologies related to gene therapies and gene-modified cell therapies.Les EchosSartorius acquiert Polyplus auprès d’ArchiMed et Warburg PincusSartorius Stedim Biotech (SSB) is acquiring the cell and gene therapy technology provider Polyplus from its current owners, ArchiMed and Warburg Pincus. The transaction involves SSB, a Paris-listed group with €3.5 billion in revenue that is majority-controlled by the German company Sartorius.SartoriusSartorius to acquire PolyplusSartorius has signed an agreement to acquire France-based Polyplus for approximately 2.4 billion euros from private investors including ARCHIMED and Warburg Pincus. The acquisition aims to combine Sartorius's bioprocess solutions with Polyplus's transfection reagents and plasmids, which are key components in manufacturing viral vectors for cell and gene therapies. The transaction is expected to close during the third quarter of 2023, subject to regulatory approvals and works council consultation.BioProcess InternationalPolyplus adds plasmid DNA CDMO Xpress BioPolyplus has acquired Belgian CDMO Xpress Biologics to expand its plasmid DNA and protein production capabilities. This move, following the earlier acquisition of e-Zyvec, aims to strengthen Polyplus' upstream toolbox and reduce costs for cell and gene therapy manufacturing through improved process economics.PR Newswire$1.6 Billion Worldwide Transfection Technologies Industry to 2027 - Featuring Lonza, Maxcyte, Mirus Bio and Polyplus Transfection Among OthersResearch and Markets published a global transfection technologies market report showing the market reached $992.8 million in 2021 and is projected to grow to $1.6 billion by 2027, representing an 8.5% compound annual growth rate. The market growth is driven by increasing cancer and chronic disease prevalence, adoption of reagent-based and instrument-based transfection methods, and technological advancements in cell research and therapeutic discovery. Government and private investments in large-scale transfection facilities and R&D in protein therapeutics are expected to further fuel market expansion.PR NewswireInsights on the Transfection Reagents and Equipment Global Market to 2027 - by Product, Technology, Application, End-user and RegionResearch and Markets has published a global market report on transfection reagents and equipment, valued at US$824.2 million in 2021 and projected to reach US$1,322.50 million by 2027, growing at a CAGR of 7.70%. Key growth drivers include increased demand for vaccine development and gene therapies amid COVID-19, rising cancer research activity, and advancements in tissue engineering and precision medicine.